ES2196016T3 - Proteina p140 y dna que codifica para la indicada proteina. - Google Patents
Proteina p140 y dna que codifica para la indicada proteina.Info
- Publication number
- ES2196016T3 ES2196016T3 ES94118524T ES94118524T ES2196016T3 ES 2196016 T3 ES2196016 T3 ES 2196016T3 ES 94118524 T ES94118524 T ES 94118524T ES 94118524 T ES94118524 T ES 94118524T ES 2196016 T3 ES2196016 T3 ES 2196016T3
- Authority
- ES
- Spain
- Prior art keywords
- protein
- prevention
- treatment
- phosphorilation
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 abstract 7
- 238000000034 method Methods 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000003345 hyperglycaemic effect Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008054 signal transmission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
LA PRESENTE INVENCION ESTA RELACIONADA CON UN NUEVO POLIPEPTIDO DE LA PROTEINA P140 QUE ES UNA PROTEINA CLAVE IMPLICADA EN EL SISTEMA DE TRANSMISION DE SEÑAL DE LA INSULINA; EL METODO PARA LA PREPARACION DE ELLA; EL DNA QUE CODIFICA DICHO POLIPEPTIDO; EL VECTOR DERIVADO DE DICHO DNA; LAS CELULAS HUESPED TRANSFORMADAS AL DICHO VECTOR; EL ANTICUERPO DEL DICHO POLIPEPTIDO; LA COMPOSICION FARMACEUTICA QUE CONTIENE DICHO PEPTIDO O ANTICUERPO; EL METODO PARA LA PREVENCION Y/O TRATAMIENTO DE LA DIABETES, QUE ESTA CARACTERIZADO POR LA FOSFORILACION DE TIROSINA DE DICHA PROTEINA P140; EL AGENTE PARA LA PREVENCION Y/O TRATAMIENTO PARA LA ACTUALIZACION DE DICHO METODO DE TRATAMIENTO Y/O PREVENCION; EL AGENTE PARA LA PREVENCION Y/O TRATAMIENTO DE LA DIABETES, QUE ESTA CARACTERIZADA POR CONTENER UN COMPONENTE QUE PUEDA LA FOSFORILACION DE TIROSINA DE LA PROTEINA P140, COMO INGREDIENTE ACTIVO Y LOS METODOS DE PROTECCION DE DICHO AGENTE DE TRATAMIENTO Y/O PREVENCION. LA FOSFORILACION DE TIROSINA DE LA PROTEINA P140 ES UN PASO ESENCIAL EN LA INDUCCION DE LA HIPOGLUCEMIA POR LA CAPTACION DE GLUCOSA. EL METODO Y EL AGENTE DE PREVENCION Y/O TRATAMIENTO BASADO EN LA FOSFORILACION DE TIROSINA DE LA PROTEINA P140 EN LA PRESENTE INVENCION NO SOLAMENTE MEJORA LAS CONDICIONES HIPERGLICEMICAS DERIVADAS DE LA DIABETES SINO SON TAMBIEN UTILES PARA EL TRATAMIENTO Y/O PREVENCION DE LA DIABETES, ESPECIALMENTE MELLITUS DE DIABETES NO DEPENDIENTE DE INSULINA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31580693 | 1993-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2196016T3 true ES2196016T3 (es) | 2003-12-16 |
Family
ID=18069786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94118524T Expired - Lifetime ES2196016T3 (es) | 1993-11-24 | 1994-11-24 | Proteina p140 y dna que codifica para la indicada proteina. |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US5506205A (es) |
| EP (1) | EP0659883B1 (es) |
| KR (1) | KR100256664B1 (es) |
| CN (1) | CN1057096C (es) |
| AT (1) | ATE237683T1 (es) |
| CA (1) | CA2136565C (es) |
| DE (1) | DE69432511T2 (es) |
| DK (1) | DK0659883T3 (es) |
| ES (1) | ES2196016T3 (es) |
| PT (1) | PT659883E (es) |
| TW (1) | TW311913B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506205A (en) * | 1993-11-24 | 1996-04-09 | Ono Pharmaceutical Co., Ltd. | Polypeptide of protein p140 and DNAs encoding it |
| CA2438641A1 (en) | 2001-02-15 | 2002-08-22 | King Pharmaceuticals, Inc. | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| GB0208089D0 (en) | 2002-04-09 | 2002-05-22 | Oxford Glycosciences Uk Ltd | Protein |
| EP2046313A4 (en) * | 2006-07-10 | 2012-01-25 | Glucox Biotech Ab | USE OF NAPHTHOCHINONES IN THE TREATMENT AND CONTROL OF DIABETES, INSULIN RESISTANCE AND HYPERGLYCEMIA |
| US8440208B2 (en) * | 2007-05-01 | 2013-05-14 | Board Of Regents, The University Of Texas System | Chlamydial antigens as reagents for diagnosis and treatment of chlamydial infection and disease |
| US7892567B2 (en) * | 2007-10-01 | 2011-02-22 | Board Of Regents, The University Of Texas System | Methods and compositions for immunization against chlamydial infection and disease |
| JP4798125B2 (ja) * | 2007-12-13 | 2011-10-19 | 株式会社デンソー | 照度センサ |
| CN105085630A (zh) * | 2015-08-31 | 2015-11-25 | 苏州普罗达生物科技有限公司 | mTOR抑制多肽及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260200A (en) * | 1991-01-18 | 1993-11-09 | Joslin Diabetes Center, Inc. | Isolated DNA encoding an insulin receptor substrate |
| US5811396A (en) * | 1991-03-14 | 1998-09-22 | The United States Of America As Represented By The Department Of Health And Human Services | TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor |
| US5506205A (en) * | 1993-11-24 | 1996-04-09 | Ono Pharmaceutical Co., Ltd. | Polypeptide of protein p140 and DNAs encoding it |
-
1994
- 1994-11-23 US US08/348,143 patent/US5506205A/en not_active Expired - Fee Related
- 1994-11-24 EP EP94118524A patent/EP0659883B1/en not_active Expired - Lifetime
- 1994-11-24 DK DK94118524T patent/DK0659883T3/da active
- 1994-11-24 DE DE69432511T patent/DE69432511T2/de not_active Expired - Fee Related
- 1994-11-24 PT PT94118524T patent/PT659883E/pt unknown
- 1994-11-24 CA CA002136565A patent/CA2136565C/en not_active Expired - Fee Related
- 1994-11-24 KR KR1019940031010A patent/KR100256664B1/ko not_active Expired - Fee Related
- 1994-11-24 ES ES94118524T patent/ES2196016T3/es not_active Expired - Lifetime
- 1994-11-24 CN CN94119935A patent/CN1057096C/zh not_active Expired - Fee Related
- 1994-11-24 AT AT94118524T patent/ATE237683T1/de not_active IP Right Cessation
- 1994-12-13 TW TW083111593A patent/TW311913B/zh active
-
1995
- 1995-12-13 US US08/571,785 patent/US5804411A/en not_active Expired - Fee Related
-
1998
- 1998-01-08 US US09/192,435 patent/US6303320B1/en not_active Expired - Fee Related
-
2000
- 2000-04-26 US US09/558,340 patent/US6432913B1/en not_active Expired - Fee Related
-
2002
- 2002-07-03 US US10/187,958 patent/US20030170865A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69432511D1 (de) | 2003-05-22 |
| DE69432511T2 (de) | 2004-04-29 |
| TW311913B (es) | 1997-08-01 |
| US5804411A (en) | 1998-09-08 |
| US6432913B1 (en) | 2002-08-13 |
| CN1057096C (zh) | 2000-10-04 |
| EP0659883A2 (en) | 1995-06-28 |
| EP0659883A3 (en) | 1997-06-25 |
| CA2136565C (en) | 1999-11-09 |
| KR100256664B1 (ko) | 2000-05-15 |
| EP0659883B1 (en) | 2003-04-16 |
| US5506205A (en) | 1996-04-09 |
| US20030170865A1 (en) | 2003-09-11 |
| CA2136565A1 (en) | 1995-05-25 |
| KR950014135A (ko) | 1995-06-15 |
| ATE237683T1 (de) | 2003-05-15 |
| DK0659883T3 (da) | 2003-08-04 |
| CN1112127A (zh) | 1995-11-22 |
| US6303320B1 (en) | 2001-10-16 |
| PT659883E (pt) | 2003-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Turner et al. | COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee | |
| Steinritz et al. | Medical documentation, bioanalytical evidence of an accidental human exposure to sulfur mustard and general therapy recommendations | |
| Leong et al. | Cross neutralization of Afro-Asian cobra and Asian krait venoms by a Thai polyvalent snake antivenom (Neuro Polyvalent Snake Antivenom) | |
| Loughnan et al. | Chemical and functional identification and characterization of novel sulfated α-conotoxins from the cone snail conus a nemone | |
| Sarac et al. | Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo | |
| CN100360184C (zh) | 稳定等渗的冻干蛋白质制剂 | |
| PE20040560A1 (es) | Preparaciones acidas de insulina con estabilidad mejorada | |
| Willis et al. | The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison | |
| ES2196016T3 (es) | Proteina p140 y dna que codifica para la indicada proteina. | |
| Leong et al. | Immunological cross-reactivity and neutralization of the principal toxins of Naja sumatrana and related cobra venoms by a Thai polyvalent antivenom (Neuro Polyvalent Snake Antivenom) | |
| CN101172100A (zh) | 稳定等渗的冻干蛋白质制剂 | |
| ATE165976T1 (de) | Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente | |
| Nahai et al. | IncobotulinumtoxinA (Xeomin) Background, Mechanism of Action, and Manufacturing | |
| Mancuso et al. | Emicizumab prophylaxis in adolescent/adult patients with hemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 study | |
| Woodley et al. | Recessive dystrophic epidermolysis bullosa: advances in the laboratory leading to new therapies | |
| Chen et al. | A neuropeptide Y/F-like polypeptide derived from the transcriptome of Turbinaria peltata suppresses LPS-induced astrocytic inflammation | |
| Andreosso et al. | Dose and time dependence of box jellyfish antivenom | |
| Roine et al. | Randomized trial of fourvs. seven days of ceftriaxone treatment for bacterial meningitis in children with rapid initial recovery | |
| Harro et al. | Clearance of Staphylococcus aureus from in vivo models of chronic infection by immunization requires both planktonic and biofilm antigens | |
| Hawking et al. | The trypanocidal action of human serum and of baboon plasma | |
| Guan et al. | TGFβ-1 and neurological function after hypoxia-ischemia in adult rats | |
| Iozzo et al. | Senile lower lid entropion successfully treated with botulinum toxin A | |
| Penggabean et al. | Efficacy of albendazole in the treatment of Trichuris trichuria and Giardia intestinalis infection in rural Malay communities. | |
| Hekman et al. | Isolation and identification of cyclic imide and deamidation products in heat stressed pramlintide injection drug product | |
| DK0653939T3 (da) | Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner |